Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 150 participants.

Also called NCT05473520

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05473520
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Malaysia, Singapore (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05473520. Randomized; quadruple masking; primary purpose treatment. Start 2023-05-24 (actual); primary completion 2030-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
Acronym
Doxy-TB
Condition
Tuberculosis
Condition
Acute Coronary Syndrome
Condition
Pulmonary Hypertension (Diagnosis)
Intervention (Drug)
Doxycycline
Intervention (Drug)
Placebo
Lead sponsor
National University Hospital, Singapore (class: other)
Collaborator
Tan Tock Seng Hospital (class: other)
Collaborator
Hospital Queen Elizabeth, Malaysia (class: other government)
Collaborator
National University of Singapore (class: other)
Collaborator
University Malaysia Sabah (class: not stated)
Collaborator
Menggatal Health Clinic, Sabah, Malaysia (class: not stated)
Collaborator
Luyang Health Clinic, Sabah, Malaysia (class: not stated)

Record details

Record id
cardio:ct-nct05473520
Content hash
f1c1f0f8ddbf08b544f47ae11fd230046bf7f7d57b89b5f1d7e6a0a2b936a135